Get the Stockscreener App
18.83
0.75%
0.14
After Hours:
18.83
Kodiak Sciences Inc stock is traded at $18.83, with a volume of 760.74K.
It is up +0.75% in the last 24 hours and up +19.18% over the past month.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
See More
Previous Close:
$18.69
Open:
$19.21
24h Volume:
760.74K
Relative Volume:
0.88
Market Cap:
$994.63M
Revenue:
-
Net Income/Loss:
$-197.68M
P/E Ratio:
-5.008
EPS:
-3.76
Net Cash Flow:
$-158.88M
1W Performance:
+6.38%
1M Performance:
+19.18%
6M Performance:
+357.59%
1Y Performance:
+403.48%
1-Day Range:
$18.18
$19.27
1-Week Range:
$16.25
$20.13
52-Week Range:
$1.92
$20.13
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1200 PAGE MILL RD, PALO ALTO, CA
Compare KOD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
18.83 | 987.24M | 0 | -197.68M | -158.88M | -3.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.17 | 108.04B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
478.58 | 60.75B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.31 | 61.26B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
829.83 | 50.32B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
164.02 | 33.75B | 398.11M | -1.03B | -868.57M | -5.7032 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-25-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-22-25 | Initiated | Jefferies | Buy |
| Aug-14-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Can technical indicators confirm Kodiak Sciences Inc.’s reversalJuly 2025 EndofMonth & Growth Oriented Trading Recommendations - newser.com
Applying Elliott Wave Theory to Kodiak Sciences Inc.Watch List & Entry Point Confirmation Signals - newser.com
Is Kodiak Sciences Inc. stock a safe haven assetGap Up & Consistent Profit Focused Trading Strategies - newser.com
Is Kodiak Sciences Inc. trending in predictive chart modelsAnalyst Downgrade & Weekly High Return Stock Forecasts - newser.com
What makes Kodiak Sciences Inc. (K27) stock appealing to growth investorsEntry Point & Community Trade Idea Sharing Platform - newser.com
Is Kodiak Sciences Inc. stock ready for a breakoutM&A Rumor & Safe Capital Growth Stock Tips - newser.com
Why Kodiak Sciences Inc. (K27) stock is a strong analyst pickJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - Fundação Cultural do Pará
How Kodiak Sciences Inc. stock reacts to Fed rate cutsEarnings Trend Report & Long Hold Capital Preservation Plans - newser.com
How to manage a losing position in Kodiak Sciences Inc.2025 Key Highlights & Weekly High Return Stock Opportunities - newser.com
Can Kodiak Sciences Inc. (K27) stock attract ESG investmentsWeekly Volume Report & Weekly Chart Analysis and Guides - newser.com
How geopolitical risks impact Kodiak Sciences Inc. (K27) stockMarket Movement Recap & Real-Time Buy Zone Alerts - newser.com
Will Kodiak Sciences Inc. stock deliver consistent dividendsBear Alert & Momentum Based Trading Signals - newser.com
Will Kodiak Sciences Inc. (K27) stock keep raising dividendsMarket Activity Report & Fast Moving Stock Watchlists - newser.com
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
2.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):